Generation Bio Revenue and Competitors
Estimated Revenue & Valuation
- Generation Bio's estimated annual revenue is currently $38.4M per year.
- Generation Bio received $100.0M in venture funding in February 2018.
- Generation Bio's estimated revenue per employee is $207,760
- Generation Bio's total funding is $460.4M.
- Generation Bio's current valuation is $396.7M. (January 2022)
- Generation Bio has 185 Employees.
- Generation Bio grew their employee count by 6% last year.
Generation Bio Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Generation Bio?
Generation Bio is creating a revolutionary new class of genetic medicines that deliver durable, high levels of gene expression and have drug-like properties, including ability to titrate to effect and re-dose. Our unique GeneWave technology allows us to overcome the limitations of other approaches by delivering larger genes, including more sophisticated regulatory elements, and avoiding the immunogenicity which limits both the number of patients who can be treated and the ability to re-dose them over time. We are a community of creative problem-solvers and independent thinkers. We are guided by strong personal integrity, humility, and the collaborative, learning mindset required to create solutions for patients and their families. To learn more about our efforts to usher in a new generation in medicine, please visit www.generationbio.com or our Twitter feed, @lifetimegeneTX.keywords:N/A
Number of Employees
Employee Growth %
Generation Bio News
Data Bridge Market Research has used a versatile approach to focus attention on Demand and Sales of Next Generation Bio-therapeutics Market.
Generation Bio Co (GBIO) is around the top of the Biotechnology industry according to InvestorsObserver. GBIO received an overall rating of...
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for...
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform Potent factor VIII construct optimized by ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-e ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Generation Bio Funding
|2018-02-28||$100.0M||B||Fidelity Management & Research Company||Article|